Pure erythroid leukemia in a polymyositis patient treated with azathioprine. (10th May 2018)

• Record Type: Journal Article
• Authors: Imataki, Osamu; Takeuchi, Akihiro; Uchida, Shumpei; Yokokura, Shigeyuki; Uemura, Makiko; Kadowaki, Norimitsu
• Is Part Of: Rare tumors. Volume 10(2018)
• Publication Date: 2018-05-10
• Subjects: Acute myeloid leukemia -- pure erythroid leukemia -- erythroleukemia -- polymyositis -- azathioprine -- myelodysplastic syndrome; Rare diseases -- Periodicals; Tumors -- Periodicals; Neoplasms; Rare Diseases; Rare diseases; Tumors; Case Reports; Periodicals; Periodicals; 616.994
• DOI: 10.1177/2036361318773847
• Languages: English
• ISSNs: 2036-3613

Abstract

Acute erythroid leukemia, also known as acute myeloid leukemia-M6, may be associated with previous chemotherapy or immunosuppressive therapy. For 10 years, a 69-year-old Japanese female patient with pure erythroid leukemia (or acute myeloid leukemia-M6b) was treated for polymyositis with 50–100 mg/day azathioprine. She complained of dyspnea with low-grade fever and was diagnosed as having pure erythroid leukemia. Chromosomal analysis revealed a complex karyotype abnormality, with the deletion of 5q, -6, -7 and addition of 11q13. No morphological myelodysplastic changes were observed in her bone marrow cells. In this study, azathioprine accumulation was considered to be associated with the patient's leukemogenesis.